Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q4 2024 value amounting to $11.7 million.

  • Syndax Pharmaceuticals' Gains from Investment Securities rose 938.92% to $11.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.7 million, marking a year-over-year increase of 938.92%. This contributed to the annual value of $11.7 million for FY2024, which is 938.92% up from last year.
  • According to the latest figures from Q4 2024, Syndax Pharmaceuticals' Gains from Investment Securities is $11.7 million, which was up 938.92% from $10.7 million recorded in Q4 2023.
  • In the past 5 years, Syndax Pharmaceuticals' Gains from Investment Securities ranged from a high of $17.0 million in Q4 2022 and a low of -$3000.0 during Q3 2020
  • In the last 5 years, Syndax Pharmaceuticals' Gains from Investment Securities had a median value of $1.1 million in 2020 and averaged $4.2 million.
  • Examining YoY changes over the last 5 years, Syndax Pharmaceuticals' Gains from Investment Securities showed a top increase of 6446363.64% in 2020 and a maximum decrease of 15000.0% in 2020.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Gains from Investment Securities stood at $7.1 million in 2020, then soared by 42.2% to $10.1 million in 2021, then soared by 68.33% to $17.0 million in 2022, then crashed by 37.15% to $10.7 million in 2023, then increased by 9.39% to $11.7 million in 2024.
  • Its last three reported values are $11.7 million in Q4 2024, $10.7 million for Q4 2023, and $308550.0 during Q3 2023.